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Key points:  
 
 
Coroner’s reports are a potentially rich source of data on fatal medication errors and adverse 
drug reactions 
 
Opiate and anticoagulation medication account for nearly half of fatal medication errors 
mentioned in coroners’ reports to prevent future deaths 
 
Health organisations, professional and regulatory bodies, and market authorisation holders 
could derive wider pharmacovigilance benefits from greater awareness of coroners’ reports 
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Abstract 
Introduction: Since legislation in 2009, coroners in England and Wales must make reports in 
cases where they believe it is possible to prevent future deaths.   We categorized the reports 
and examined whether they could reveal preventable medication errors or novel adverse drug 
reactions. 
Methods: We examined 500 coroners’ reports by pre-defined criteria to identify those in 
which medicines played a part, and to collect information on coroners’ concerns. 
Results: We identified 99 reports (100 deaths) in which medicines or a 
part of the medication process or both were mentioned.   Reports mentioned anticoagulants 
(25 deaths), opioids (24), antidepressants (18), drugs of abuse excluding opioids (13 deaths), 
and other drugs. The most important concerns related to adverse reactions to prescribed 
medicines (22), omission of necessary treatment (21), failure to monitor treatment (17), and 
poor systems (17).  These were related to defects in education or training, lack of clear 
guidelines or protocols, and failure to implement existing guidelines, among other reasons. 
Most reports went either to NHS Hospital Trusts or to local trusts. The responses of 
addressees were rarely published. We identified four safety warnings from the Medicines and 
Healthcare products Regulatory Agency that were based on coroners’ warnings.  
Conclusion: Coroners’ reports to prevent future deaths provide some information on 
medication errors and adverse reactions. They rarely identify new hazards. At present they 
are often addressed to local bodies, but this could mean that wider lessons are lost.  
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1. Introduction 
In England and Wales, the cause of deaths other than natural deaths is established at inquest, 
conducted by a coroner. Since 2009 coroners have had a duty to make reports to a person, 
organisation, local authority or government department or agency where the coroner believes 
that action should be taken to prevent future deaths. [1] 
 
These ‘Reports to Prevent Future Deaths’ (known as PFDs) are published on the website of 
the Courts & Tribunals Judiciary. [2] The legal powers underpinning the PFD are set out in 
paragraph 7, schedule 5 of the Coroners and Justice Act 2009 and regulations 28 and 29 of 
the Coroners (Investigations) Regulations 2013.  
 
We wished to examine PFDs to establish how often medicines and other drugs (excluding 
alcohol) were referred to in reports, and the nature of recommendations, and the extent to 
which they revealed preventable medication errors or novel adverse drug reactions.  
 
2. Methods 
We decided whether reports should be included in our study using the algorithm shown in 
Figure 1.   
 
{Figure 1 near here} 
 
If the PFD mentioned part of the medication process (for example, administration), or if a 
medicine was mentioned, or both; and either caused or contributed to death, then we included 
the report. We included drugs of abuse such as diamorphine (heroin) and cocaine. We 
excluded those cases in which a medicine or part of the medication process was mentioned, 
but did not cause or contribute to death; and in which delays in assessment, investigation, or 
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diagnosis led to delays in treatment. We also excluded cases where the only drug mentioned 
was alcohol.  
 
The 500 reports from 24th April 2015 to 7th September 2016 were downloaded from the 
Courts and Tribunals Judiciary website. Two of us (CE and REF) each categorized all the 
PFDs. Where there was uncertainty, the categorization was resolved by discussion; 
disagreements were resolved by adjudication (by ARC).  
 
The data from each of the included PFDs were extracted in standard form. After the case 
reports were categorised into the four separate groups, as described above, the following 
information was recorded in a Microsoft Excel® spreadsheet for all cases: 
x Patient Name, age or date of birth and date of death 
x Jurisdiction in which death occurred 
x Catalogue number 
In the case of a medication error, the following information was also recorded: 
x Gender and medical and social history of the patient 
x The medical cause of death/conclusion of the coroners’ inquest 
x Nature of the medication error 
x Circumstances surrounding the medication error and how, if applicable, did the error 
occur 
x Coroner recommendation 
x Coroners recommendation classification 
x Whether the report had been classified under the alcohol, drug and medication 
classification on the Judiciary website 
x Medication error classification 
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x The drug class of the medication involved 
x Setting of patient death e.g. hospital/ community/care home/ state 
 
 
We used the information within the PFDs to categorize the role that a drug had played in 
causing or contributing to a person’s death, and by implication those matters that required 
attention. We also considered whether the report described a previously recognized hazard, 
and whether it was of general relevance. 
 
PFDs are directed to specific individuals or organisations, and we also examined whom they 
were addressed to.  
We used only information in the public domain, and did not seek ethics committee approval. 
 
3. Results 
We identified 99/500 PFDs which fulfilled the criteria, and which related to 100 people. 
Details are given in the Supplementary Table. 
 
{Supplementary Table}.  
 
Forty two of the 100 people we identified were women; 54 deaths were recorded in 2015 and 
46 in 2016. The age was stated in 2/3 of reports, among whom the mean age was 52 years 
and median age 50 years [range 1 day to 96 years]. The drug classes implicated are shown in 
Table 1.  
  
{Table 1 near here} 
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Most frequently mentioned drug classes, used alone or in combination, were anticoagulants 
(in 22 cases) and opioids, whether or not prescribed (in 17 cases). Other drugs of abuse 
included ecstasy (3 deaths), cannabis or cannabinoids (4 deaths), and cocaine (2 deaths). 
 
 The concerns expressed by coroners are categorized in Table 2, which also lists the number 
of cases in which an adverse drug reaction (ADR) to a prescribed medicine was recorded.  
 
{Table 2 near here} 
 
We also categorized the Coroners’ concerns according to a pre-determined list of terms. In 58 
instances, coroners were concerned about the absence of protocols or guidelines; or the need 
to update them; or the failure to enforce them. Concerns centred on education and training in 
33 reports; and on difficulties in communication in 21 reports. Coroners were also concerned 
about standards of review or monitoring (24 reports), drug regulation (12 reports), and issues 
related to staff or equipment (13 reports). We concluded that reports mostly (76) concerned 
local failure or bad practice, and generally (52) served as a reminder of known risks. Many 
(57) would be of wide relevance to patients and healthcare professionals who wished to 
mitigate risks in the health service. One report concerned a possible new risk in the 
manufacture of slow-release fentanyl patches, and 12 suggested failures in drug regulation, 
although the failures (principally in the control of novel psychoactive substances) had 
previously been recognized. The implications of two of the reports were uncertain.  
   
At least 15% of the reports involved patients in care homes, and reflect a change in the 
regulations for enquiries into cases where people have been deprived of their liberty. Almost 
a third of all reports concerned drugs of abuse. Of these, several occurred in prison, and in 
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total nearly 10% of the reports related to deaths in police custody or prison, a further issue of 
current concern.  
 
Table 3 lists the agencies or persons to whom reports were addressed, and who had a duty to 
respond to the coroner’s report within 56 days of the date on which it was issued.  
 
{Table 3 near here} 
 
While there is the opportunity for responses to be posted on the internet, this was rarely done. 
Some responses were clear. For example, MHRA published warnings about fentanyl patches 
[Cases 2015-0463 and 2016-0014], emollients [Cases 2015-0317 and 2016-0163], the 
interaction between cocaine and citalopram [Case 2015-0231], and cardiac effects of 
hyoscine butylbromide [Case 2016-0308], although reports were only specifically addressed 
to MHRA in the last two cases.  
 
3.1 Examples of Coroners’ concerns 
a) An adverse drug reaction that was missed – perforation of a gastric ulcer [Case 2016-
0222] 
A 16-year-old girl with cerebral palsy and other difficulties was treated with medicines 
including diclofenac. She appeared to be in pain with abdominal distension. The general 
practitioner saw her and arranged admission, but the junior doctor who clerked the patient did 
not see the admission letter, and diagnosed constipation. As the patient’s pulse rate was 
increased, an electrocardiogram was arranged. This showed only sinus tachycardia. The 
patient was discharged with a laxative. When she represented the next morning, she was 
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gravely ill, and she died soon afterwards from peritonitis secondary to a perforated gastric 
ulcer. 
The Coroner expressed concern that no cause was sought for the tachycardia; that there were 
failings in the record-keeping, and that the general practitioners record never reached the he 
junior doctor; and that the possibility of diclofenac-induced ulceration and perforation was 
not considered.  
 
b) The danger of high doses of heroin in addicts who have lost tolerance [Case 2016-
0058] 
A 25-year-old man with a history of depression and substance misuse was referred to a 
psychiatric team specializing in patients with ‘dual diagnoses.’ Appointments were delayed. 
The man managed to reduce his own opiate usage. He then received a benefits payment, took 
a large dose of heroin, and died.  
The Coroner expressed concerns regarding the various agencies involved, and their failure to 
communicate with each other. The coroner did not explicitly state that addicts should be 
educated about the dangers of taking large doses after tolerance has lapsed.  
 
c) An under-appreciated danger from paraffin-based emollients [Cases 2015-0317 and 
2016-0163]. 
Two reports described the deaths of incapacitated patients who suffered fatal burns when 
dressings that had become impregnated with paraffin-containing emollients dropped smoking 
materials onto themselves. Coroners expressed concerns that the dangers were not widely 
recognized, and warnings insufficient. 
 
d) Failures of medication control in prisons [Case 2015-0468] 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 10 
 
A male prisoner was found collapsed by his cell-mate in the early hours of the morning. 
Toxicological samples showed the presence of prescribed and non-prescribed drugs, 
including methadone, buprenorphine, diazepam, pregabalin, quetiapine, and a synthetic 
cannabinoid. Both prescribed and non-prescribed drugs were found hidden in his cell. 
The Coroner expressed concern that prison staff lacked awareness and understanding of 
drugs; that there was a failure to use a multi-disciplinary approach to the problem; that 
medicines could easily be concealed; that prisoners are not adequately monitored; that 
positive drug test results were not shared with prison staff; and that drugs could easily be 
smuggled or thrown into the prison.  
 
e) Secondary risks of drug therapy – haemorrhage after trauma in a patient taking 
warfarin 
A woman took warfarin for an established heart condition. She went to meet a friend at a 
supermarket café and took the lift to the mezzanine. In the lift she leant on the rear wall, 
which was in fact a door that opened without warning. The woman stumbled, fell, and banged 
her head. She consequently developed a fatal intracerebral haemorrhage.  
The Coroner was concerned that the rear door was not marked in any way, and that no 
warning sounded when the door opened.  
 
A brief description of each of the 100 included deaths (99 reports) is provided in the 
Supplementary Table.  
 
There were several ‘grey’ cases that we excluded from the analysis. For example, in one 
report, the coroner stated that an elderly woman had been given too much heparin because the 
dosage calculated had failed to take into account that she weighed only 30 kg. However, the 
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report also explicitly stated that this failure did not cause or contribute to death. [Case 2015-
0417]. In another example, a young man died from abusing helium, breathed from a plastic 
bag. Although the coroner stated that helium was toxic, it is only toxic in the sense that—like 
nitrogen—it cannot support life without the addition of oxygen; and nor is it regarded as a 
medicine. [Case 2016-0182]. In a third case, a patient died from complications of tracheal 
stenosis after prolonged intensive care, itself a consequence of severe ketoacidosis from new-
onset diabetes. The coroner noted that the patient was treated with clozapine, which can 
precipitate diabetes, and criticized the failure to monitor blood glucose concentrations during 
clozapine treatment, but the Summary of Product Characteristics for clozapine recommends 
periodic measurement of fasting blood glucose concentration only in those with risk factors 
for diabetes. [Case 2015-0194]. 
 
4. Discussion 
The primary purpose of a Coroner’s Inquest is to establish in the case of an unexplained death 
who has died, when and where they did so, and what led to death. It is inevitable, in 
conducting enquiries sufficient to provide this information, that Coroners will uncover factors 
that led to the individual death and which may in future lead to further deaths.  
 
Coroners in England and Wales have, under Rule 43 of the Coroners Rules 1984, been able to 
make reports with the intention of preventing future deaths. In the updated legislation of 2008 
and 2013, Coroners now have a duty to make such reports where they are appropriate, and 
these reports are available on the internet. Similar provision has been made elsewhere, for 
example, in New Zealand, [3] Australia, [4,5] and Canada [6]. In the United Kingdom, 
coroners are not permitted to make recommendations of improvements in PFDs, which do not 
therefore set out explicitly the ways in which improvements might be made. 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 12 
 
 
In 2015 there were 529 613 deaths in England and wales, and of these 236 406 (45%) were 
reported to a coroner. [7]   Coroners requested post-mortem examinations in nearly 90 000 
deaths, and opened 32 857 inquests. Of 35 473 inquests concluded, death was recorded as 
non-natural on 24 430 occasions (69%) (The number of inquests completed exceeded the 
number of inquests opened as a consequence of a conscious decision by the Ministry of 
Justice to clear a historical backlog of cases). Of these deaths, 2% were related to road traffic 
collision, 6% to drugs or alcohol, 11% to suicide, and 22% to accident or misadventure. 
During 2015, the website of the Courts and Tribunals Judiciary listed PFDs with serial 
numbers from 0001 to 0502; [8] occasional reports concerned more than one death. The next 
year, the serial numbers of PFDs ran from 0001 to 0467.  
 
The Courts and Tribunals Judiciary website categorizes reports. One of the classifications is 
‘Alcohol, drug and medication deaths.’ During the period of our study, only eight reports 
were categorized as ‘Alcohol, drug and medication related deaths’ on the website; one of 
these concerned a man who was hit by a train, having probably wandered onto a railway line 
while drunk [Case 2016-0234], so that only seven fulfilled our criteria. We do not know the 
criteria by which the reports are classified on the website, but the vast majority of the reports 
we identified are omitted. This failure to classify deaths as related to medications may 
impede the use of coroner reports as an additional source of pharmacovigilance data by 
regulatory authorities and market authorisation holders. 
 
Coroners expressed concern in 33 reports that failures in education and training had 
contributed to death, and in a further 27 reports that absent or unsatisfactory protocols had 
contributed. Difficulties in communication (21 reports) and failure to adhere to pre-existing 
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protocols (20 reports) also featured prominently among concerns. The failure to observe pre-
existing protocols suggests that introducing new protocols will not always protect against 
future risk.  
 
The coroners’ reports dealt with a range of drugs and medicines. The medicines involved 
were largely predictable, and few of the reported problems were novel. The most commonly 
represented were anti-coagulants (25 deaths), opioids (22 deaths), and anti-depressants (17 
deaths). Drugs of abuse excluding opioids were mentioned in 12 cases. Four of these cases, 
related to cannabis or synthetic cannabinoids, were among 11 deaths in prison or in police 
custody. The reports on deaths in custody suggest both that synthetic cannabinoids and other 
drugs of abuse are readily available in prison, and that there are dangers in the unsupervised 
medication of prisoners, who are able to hide drugs dispensed to themselves or acquired from 
others.  
 
Coroners reported failures in the laws governing the misuse of drugs, and the reports have 
been followed by the introduction of the Psychoactive Substances Act 2016, which controls 
the production, supply, and sale of substances, intended for human consumption, that are 
"capable of producing a psychoactive effect". Parliament discussed both the availability of 
synthetic cannabinoids (‘legal highs’) in prison, and deaths from legal highs, but it is unclear 
whether the coroners’ reports influenced the legislators. [9]. 
 
The influence of coroners’ reports was more certain in the case of the Medicines and 
Healthcare products Agency (MHRA). The Agency’s bulletin ‘Drug Safety Update’ cited the 
coroners’ reports in four articles. One warned of the danger of prescribing citalopram or other 
selective serotonin reuptake inhibitor to patients who are known to abuse cocaine. [Case 
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2015-0231;10]. A second stated that hyoscine butylbromide posed a risk of serious adverse 
effects in patients with heart disease. [Case-2016-0308; 11]. Drug Safety Update explicitly 
mentioned the coroner’s report of the angiotensin-converting-enzyme–spironolactone 
interaction that led to fatal hyperkalaemia. [Case 2015-0295; 12]. All three coroners’ reports 
had been addressed to MHRA. In addition, the coroner’s report was referenced in a Drug 
Safety Update warning of the dangers of interaction between miconazole gel and warfarin.  
[Case 2016-0096; 13]. A coroner reported a death by fire caused by a paraffin-containing 
emollient to the National Patient Safety Agency, which is now the National Reporting and 
Learning System (NRLS), part of NHS Improvement. [Case 2015-0317]. Drug Safety Update 
learnt of the incident from NRLS and reiterated earlier warnings of the fire hazard. [14]. 
 
One reason why it is difficult to be certain whether other reports have led to action is the 
relatively rare publication of responses from addressees. The system in England and Wales 
requires those to whom the report is addressed to respond within 56 days, but the responses 
are not as a matter of course posted on the internet, and so it is not possible in general to see 
whether the report has reached the addressee, whether a response had been sent to the 
Coroner, or whether any effective action has been formulated or taken. By contrast, and 
preferably, the Coronial Service of New Zealand issues six-monthly summaries of Coronial 
recommendations and responses to them. For example, a New Zealand Coroner noted that 
constipation associated with clozapine treatment could lead to fatal bowel complications, and 
that Medsafe (the New Zealand medicines regulatory authority) had warned of this for more 
than a decade prior to the death under investigation, and recommended that the local health 
board take steps to ensure care home staff looking after patients prescribed clozapine should 
be aware of Clozapine Best Practice Guidelines, and consider further training. [15].  The 
district health board accepted the recommendations and would ‘look at how the organisation 
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can strengthen responses in all of the areas noted.’ Admittedly, while the response indicates 
receipt of the recommendations, neither the coroner nor the public can know in the absence of 
further information whether any action was taken on this occasion.  
 
Coroners differ in the number, range, and influence of those to whom they addressed reports. 
Most of the reports we examined were sent to Local NHS Trusts, NHS Community 
Commissioning Groups (CCGs), or Hospital Trusts. This limits the opportunities for wider 
learning from systemic problems that might come from addressing reports to national bodies. 
For example, a coroner, concerned that a there had been a failure ‘to address the risk of 
developing diabetes’ during long-term use of olanzapine, addressed the report to the Trust 
concerned. [Case 2015-0264]. However, nearly 200, 000 prescriptions for olanzapine are 
issued every month in English CCGs, and more in mental health trusts, so that the message is 
of wide general relevance. Many of the reports described failures or adverse effects of 
general relevance. They should be integrated into national systems, and it would be 
reassuring if healthcare organizations such as the National Reporting and Learning System 
received copies of these reports so that they could inform an integrated strategy to mitigate 
harms in healthcare. 
 
Coroners are limited by the rule that they must express their concerns, but are not permitted 
to make recommendations as to how the concerns should be met. The careful enumeration of 
concerns by many coroners, but not all, implicitly invites respondents to deal with each 
concern.  
4.1 Strengths and Limitations 
We have only considered the UK coronial system. Differences in the legal and medical 
systems will influence the nature of coroners’ reports, but the principles apply to all countries 
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where coroners, medical examiners or forensic pathologists perform similar roles. The study 
is also constrained by the working practices of coroners, whose varying level of vigilance to 
drug-related deaths, and thresholds for writing a PFD report, will have influenced the 
findings. The interests of coroners and the pharmacovigilance community are only partially 
aligned, and the reports may contain limited data.  
Our study has the strength that a substantial number of coroners’ reports have been made 
since the obligation to issue PFDs was implemented.  
 
5. Conclusions 
This study is the first study to demonstrate that Coroners’ reports to prevent future deaths 
include valuable pharmacovigilance data. The reports of Coroners to prevent future deaths 
have led to wider publicity for rare but potentially fatal adverse drug reactions, and to that 
extent they have been successful. The reports might be more effective if those that related to 
NHS bodies were addressed as a matter of course to a central authority, probably either the 
National Reporting and Learning Service or the nascent Hospital Safety Investigation Branch, 
in addition to those persons and organizations currently sent reports. Unless replies are 
published as a matter of routine (and non-responders pursued), it will be difficult to judge 
whether responses have been reasonable, proportionate, and effective. Future research should 
focus on increasing the utility and visibility to pharmacovigilance professionals of Coroners’ 
work associated with drug safety issues, and examining if coroners’ reports have led to 
measurable improvements in patient safety.  
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Legends to figures and tables 
 
Figure 1. Algorithm for selection of relevant cases. If a part of the medication process 
mentioned was mentioned OR a medicine was mentioned AND it caused or contributed to the 
death, then the case was included, unless there was a delay in assessment, investigation, or 
diagnosis that led to late treatment.  
  
Supplementary Table. Cases in which coroners made reports to prevent future deaths in 
which they expressed concerns about medicines or the medication process that contributed to 
death, out of a total of 500 reports published between 24th April 2015 to 7th September 2016. 
See Electronic Supplementary Material 1. 
 
Table 1. Drug classes mentioned in coroners’ concerns, and number of cases in which one or 
more drugs of the class are mentioned. 
 
Table 2. Post hoc classification of coroners’ concerns, and number of occurrences. 
 
Table 3. Persons and organizations to whom concerns were addressed. 
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Supplementary Table 
 
[See separate file] 
 
Table 1 
 
Drug class No*  
Anticoagulants (LMWH 8, warfarin 8, NOAC 2) 22  
Opioids (fentanyl 3, methadone 4, morphine 4) 17  
Psychiatric medicines (mirtazepine 4, olanzapine 3, citalopram 4) 17 
Drugs of abuse, excluding opioids (MDMA 3, cannabinoids 4, cocaine 3, 
eCigarette fluid 1) 12 
Antibiotics 9  
Hypnotics and sedatives (lorazepam 2, zopiclone 2) 7  
Pregabalin 4  
Anticonvulsants 3  
Emollients 2  
 
LMWH = Low Molecular Weight Heparin, NOAC = Novel Oral Anti-coagulant, MDMA 
= 3-methoxy-4,5-methylenedioxyamphetamine 
*Number refers to the number of cases in which one or more drugs of the class are 
mentioned  
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Table 2 
Concern 
No of 
occurrences 
ADR to prescribed medicines 22 
Omission of necessary treatment 21 
Monitoring failure 17 
Poor systems 17 
Poor communication 13 
Drug regulation inadequate [or failure to enforce] 9 
Interaction 7 
Contra-indicated 5 
Failure of training 5 
Susceptible patient 5 
Delayed treatment 4 
Failure to appreciate risk (of recurrent or continued 
symptoms) 4 
Failure to warn of adverse drug reactions 4 
Excessive supply 3 
Failure to adjust dose 3 
Poor medicines control (in prison) 3 
Failure to follow protocol 2 
Failure to take history or see patient 2 
Inadequate training 2 
Inappropriate dose for patient 2 
Poor training 2 
Effect of medication hindered diagnosis 1 
Failure to follow recommended practice 1 
Failure to investigate whether excessive dose was given 1 
Failure to review medicines 1 
Inadequate diagnosis before prescribing 1 
Manufacturing fault in slow-release patch 1 
Poor awareness of rare adverse drug reactions 1 
Should have been avoided  1 
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Table 3 
 
Addressee No 
Advisory Council on Misuse of Drugs 3 
Ambulance 2 
British Medical Association 1 
Care Home 7 
Chief Fire Officers' Organization 1 
Brigade Chief Fire Officer 1 
Private Company (including pharmaceutical companies) 3 
Dispensing doctors’ association 1 
Department of Health 3 
Driver and Vehicle Licensing Agency 1 
Fire Officers 1 
G4S 2 
General Dental Council 1 
General Practice or practitioner 14 
Hospital 25 
Hospital doctor 2 
Hospital unit 1 
Health & Safety Executive 1 
Local authority 3 
Local NHS Trust or Clinical Commissioning Group 36 
Macmillan Cancer charity 1 
Mental Health trust 2 
Medicines & Healthcare products Regulatory Agency 4 
Minister of Health Wales 3 
Minister of Policing/crime prevention  
National Probation Service 1 
National Offender Management Service 2 
National Institute for Health and Clinical Excellence 2 
National Offender Management Service 1 
National Patient Safety Agency 1 
Nurse 2 
Omitted or anonymous 2 
Police 1 
Prison 7 
Prison Minister 4 
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Royal College of General Practitioners 1 
Royal College of Obstetrics & Gynaecology 1 
Royal College of Paediatrics & Child Health 1 
Regional NHS office 5 
Royal Pharmaceutical Society 2 
Secretary of State for Health 2 
Supermarket 1 
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Deaths from medicines: a systematic analysis of Coroners’ reports to prevent future deaths. Drug Safety. Robin E Ferner, Craig Easton, 
Anthony R Cox. Corresponding author Robin E Ferner, Email: r.e.ferner@bham.ac.uk 
 
Supplementary Table. Cases in which coroners made reports to prevent future deaths in which they expressed concerns about medicines or the 
medication process that contributed to death, out of a total of 500 reports published between 24th April 2015 to 7th September 2016. 
 
 Age & 
sex 
Case 
report no. 
To Drug Classification(s) Error Type 
1.  90 F 2016-0071 Managing director 
Cuerden Care 
Homes 
Low molecular 
weight heparin 
(dalteparin) 
Anticoagulants Extra five injections given; not 
causative. 
Care Home medication not 
sufficiently controlled – bad 
policies 
Excessive supply 
(unprescribed) 
2.  63 M 2016-0183 Chief Executive 
Officer Blackburn 
Lamotrigine 
Sodium 
valproate 
 Omitted while undergoing 
surgery 
Omission of 
necessary 
treatment 
3.  43 M 2015-0451 Medical Director 
Manchester NHS 
Area Team 
Amisulpride Psychiatric Failure to prescribe; poor 
electronic communication; failure 
to notice omission of treatment; 
schizophrenia; hanged 
Omission of 
necessary 
treatment 
4.   M 2015-0229 Chief Executive, 
Brighton 
 
Chief Nurse, 
Brighton 
 
Ward Manger, 
Brighton 
Codeine – four 
doses in 18 h 
Opioids Bipolar; fall; stage 4 kidney 
failure; pneumothorax; poisoned 
by codeine prescribed by locum; 
partial response to naloxone; 
breached local and national 
policy 
Contra-indicated 
Table Click here to download Table Supplementary Table  2017-07-27-19-05.pdf 
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5.   M 2015-
003811 
Chief Executive 
Officer Cambrian 
Group 
 
Chief Executive, 
Guys & St Thomas 
Zopiclone + 
lorazepam 
Hypnotics and 
sedatives 
Obstructive sleep apnoea; 
severe obesity; defective CPAP 
machine; poor observations; 
failure to communicate risk to 
psychiatrists 
Contra-indicated 
6.  25 F 2015-0413 Chief Executive, 
Cheltenham 
 
Head of Legal 
Services, 
Cheltenham 
Low molecular 
weight heparin 
Anticoagulant 
Anticoagulants Severe chest pain; 
anticoagulated; but pain was 
from splenic artery aneurysm 
rupture. 
Senior clinicians not involved;  
Inadequate 
diagnosis before ℞ 
7.  43 M 2016-0238 Spectrum 
Community Health 
National Offender 
Management 
Service 
 
G4S 
Medication for 
depression and 
anxiety 
Psychiatric Hanged; did not have prescribed 
treatment; awaiting review by 
GP; health professionals not 
involved in ACCT [Assessment, 
Care in Custody, Teamwork]. 
Clear need for training. 
Omission of 
necessary 
treatment 
8.  30 F 2016-0208 A GP practice 
 
North, East & West 
Devon Clinical 
Commissioning 
Group 
Paracetamol 
Pregabalin 
 Not prescribed. Down syndrome 
with learning difficulties. Mother-
in-law’s pregabalin. Overdose. 
Poor medicines 
control 
Susceptible 
patient 
(vulnerable adult) 
9.   M 2015-0394 Director, National 
Probation Service 
Heroin Opioids The lack of forward planning for 
his release from prison 
increased the risk of him using 
heroin. Discharged to Hostel, 
where he took heroin: in 
Monitoring failure 
3 
 
bathroom for 4 h before being 
found collapsed.  
10.   M 2015-0468 Director Birmingham 
Prison 
 
National Offender 
Management 
Service Birmingham,  
 
Prisons Minister 
 
Birmingham 
Community 
HealthCare NHS 
Trust 
Methadone 
Buprenorphine 
Diazepam 
Quetiapine 
Pregabalin 
Gabapentin 
Hyoscine 
5f-AKB48 
(cannabinoid) 
Opioids 
Psychiatric 
Drug of Abuse 
Hypnotics and 
sedatives 
He self‐administered various 
medication - non‐prescribed 
substance and legal highs – 
gained by exploiting 
inadequacies within the prison; 
post-mortem toxicology showed 
many drugs present. A cell 
search also found many drugs. 
Problems with screening visitors, 
checking prisoners, and so on. 
Poor medicines 
control 
11.   M 2015-0255 Chief Executive 
University Hospitals 
Leicester 
 
Chief Executive 
NHS England 
 
Chief Executive East 
Midlands Ambulance 
service 
Low molecular 
weight heparin 
(dalteparin) 
Anticoagulants Stroke; delay in hospital transfer; 
given usual daily dose of 
dalteparin 
Contra-indicated 
12.  85 M 2015-0301 Chief Executive, 
Northern General 
Sheffield & 
Cardiothoracic unit 
Amiodarone   No protocol for monitoring 
amiodarone in General Practice 
Monitoring failure 
13.  25 F 2015-0438 Head of Serious 
Incidents, Policy & 
Sertraline Psychiatric Hanged; dose of sertraline 
increased; failure to 
Failure to warn of 
ADRs 
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Patient Safety 
Directorate, Basildon 
communicate; dose of sertraline 
again increased; no proper 
medication history on 
assessment; risks of sertraline 
not communicated; prescribing 
without seeing the patients. 
Failure to take 
history or see 
patient 
14.  18 M 2016-0013 Chief Executive, 
Great Western 
Hospital 
Corticosteroids  Congenital adrenal hyperplasia; 
corticosteroid omitted after 
admission 
Omission of 
necessary 
treatment 
(Withdrawal of 
corticosteroids) 
15.  32 F 2015-0463 Teva Pharma Fentanyl Opioids Accidental overdose of 
prescribed medication. A 
damaged patch released excess 
fentanyl 
Manufacturing 
fault in slow-
release patch 
16.  80 F 2015-0196 A GP Practice 
 
Director City & 
Hackney GP 
Confederation 
Asthma pump  Treated for asthma, but had 
heart failure; Out-of-hours 
service misled by prescribed 
medicines 
Poor 
communication 
17.   M 2016-0147 Sandwell & West 
Birmingham NHS 
Trust 
 
University Hospitals 
Birmingham NHS 
Trust 
Warfarin Anticoagulants Fall, brain bleed, but slow to give 
human prothrombin complex 
(Beriplex®). Aortic valve 
replacement 
Delayed treatment 
18.  50 M 2015-0170 Senior Partner, 
Springfield Medical 
Practice 
Sodium 
valproate 
 Post traumatic epilepsy; seen at 
surgery but no enquiry regarding 
failure to obtain a prescription for 
required meds; no system to 
Omission of 
necessary 
treatment; 
Poor systems 
5 
 
highlight patients who fail to 
obtain necessary treatment 
(regarding repeat 
prescribing) 
19.  68 F 2015-04041 Chief Executive, 
Royal Bolton 
Hospital 
Lorazepam Hypnotics and 
sedatives 
Family allege that twice the 
recommended dose given; chart 
did not record this; not causal 
Failure to 
investigate 
whether excessive 
dose was given 
20.  16 F 2016-0222 Chief Executive, 
Walsall 
Diclofenac  Recognised ADR: bleeding; 
poor transmission of information; 
failure to consider drug cause 
ADR to prescribed 
medicines  
(not considered) 
21.  36 F 2016-0143 Rotherham Hospital Paracetamol  Severe malnutrition; standard 
dose of paracetamol given; but 
Mrs C weighted less than 50 kg; 
deranged blood tests of liver 
function 
Inappropriate dose 
for patient 
22.  36 M 2016-0239 Chief Executive, 
Wallich Centre 
 
Another 
Drug of abuse Drug of Abuse Hostel for the homeless. Found 
in lavatory with needle in groin. 
Helped to bed by fellow resident. 
Found dead next morning. Staff 
had no training or guidance.  
Failure of training 
Monitoring failure 
(after overdose) 
23.  50 F 2015-0410 Chief Executive, 
Nottinghamshire 
Healthcare NHS 
Trust 
Opiates 
Quetiapine 
Opioids 
Psychiatric 
Overdose after home leave. 
Assessed as at high risk. Given 
home leave the next day. Took 
fatal overdose. 
Failure of training 
Failure to 
appreciate risk (of 
further overdose) 
24.  86 F 2015-0402 Senior Partner, 
Alexander House 
Health Centre, 
Wigan 
Rivaroxiban 
Clopidogrel 
Anticoagulants  Intracerebral haemorrhage while 
on dual therapy for two different 
conditions: transient ischaemic 
attacks and atrial fibrillation. Also 
amyloid angiopathy. 
Interaction   
ADR to prescribed 
medicines Should 
have been 
avoided (NICE) 
6 
 
25.  25 M 2016-0058 Chief Executive, 
Nottinghamshire 
Healthcare NHS 
Trust 
 
Medical Director CRI 
 
Locality director for 
Nottinghamshire 
area Team 
Diamorphine Opioids Long history of substance 
abuse. Overdose. Psychiatrist’s 
assessment. Delay in 
appointments. A period of 
abstinence. A benefits pay-out. 
Heroin overdose caused death 
Monitoring Failure  
Failure to warn (of 
OD risk after 
abstinence) 
26.  29 
days,  F 
2015-0289  Department of 
Health 
Pertussis 
vaccine 
 Contrary to guidance, was not 
offered pertussis vaccine 
Omission of 
necessary 
treatment 
Poor systems 
(No way of 
ensuring 
vaccination) 
27.  83 F 2016-0252 Chief Executive 
Western Sussex 
Hospitals 
 
South East Coast 
Ambulance Service 
 
Integrated Care 24 
Ltd 
Apixaban Anticoagulants Hip fracture; nose bleed; called 
NHS 111; massive GI bleed; 
patient not given details of ADRs 
ADR to prescribed 
medicines; poor 
communication 
28.   M 2015-0273 Directors of 
Springfield Care 
Home 
Doxycycline Antibiotics Chest infection; GP prescribed 
antibiotics; home had 
Omission of 
necessary 
treatment 
7 
 
inadequate records; doxycycline 
omitted 
Poor systems 
(records 
inadequate) 
29.   M 2016-0173 Governor, HMP 
Gartree 
 
Acting Chief 
Executive, E 
Midlands Ambulance 
Service 
Prescribed and 
non-prescribed 
drugs 
 Plastic bag + overdose. 
Asphyxia and multidrug toxicity 
caused death—poor care. Took 
prescribed and non-prescribed 
drugs that he should not have 
had in his possession 
Poor medicines 
control (in prison) 
Poor systems 
30.  37 F 2015-0372 Home Secretary 
Minister of State for 
Crime Prevention 
 
Advisory Council on 
Misuse of Drugs 
Methoxy-
phenidine 
Cocaine 
Drug of Abuse Methoxyphenidine [was] not a 
controlled drug 
Drug regulation 
inadequate 
31.   M 2015-0453 National Offender 
Management 
Service 
 
G4S 
Unknown  Drugs hidden in body cavity. 
Observed to be under the 
influence of drugs. No 
assessment. Lack of 
appreciation of risk.  
Failure of training 
Monitoring failure 
(after overdose) 
32.   F 2016-0117 Acting Medical 
Director, Barts 
Morphine sulfate 
Dihydrocodeine 
Paracetamol 
Opioids Perforated caecum; caesarean; 
Ogilvie’s syndrome [colonic 
dilation]; several obstetric 
registrars were aware that the 
CT scan revealed a large 
volume in the peritoneum, but 
did not then seek a surgical 
consult 
Effect of 
medication 
hindered diagnosis 
8 
 
33.  49 M 2016-0057 Chief Executive, 
Bolton Hospital 
Antianginals  A&E does not stock; pharmacy 
prescription; pharmacy closed; 
therefore, patient did not get 
treatment 
Poor systems 
(difficult to supply 
potentially life-
saving treatment) 
34.   M 2015-0264 Chief Executive, 
Maudsley Trust 
Olanzapine Psychiatric Maudsley failed to address the 
risk of developing diabetes from 
the long-term use of olanzapine 
Monitoring failure 
35.   F 2016-0078 Chief Executive, 
Pennine Care NHS 
Foundation Trust 
 
Director of 
Commissioning/Hea
d for Mental Health, 
Rochdale, Hayward 
and Middleton CCG 
Unstated  Taken to emergency department 
acutely anxious and planning to 
jump off a viaduct: she 
subsequently ingested an 
excessive quantity of prescribed 
medication, with fatal 
consequences. The ‘Discharge 
Pad’ identified that the deceased 
was feeling suicidal and showed 
that the friend who collected her 
had expressed concern that 
Susan may take all her 
medication at once  
 
Poor medicines 
control 
36.  89 F 2015-0419 Alexandra Court 
Care Home 
Treatment for 
myasthenia 
gravis 
 Not receiving prescribed 
medication that she required to 
control the potentially life-
threatening condition 
myasthenia gravis. 
Omission of 
necessary 
treatment; 
Poor systems 
(no medicines 
reconciliation) 
37.   M 2016-0248 Alexandra Court 
Care Home 
Warfarin 
 
Anticoagulants Falls, chronic subdural 
GP was not aware he was on 
warfarin 
ADR and contraindication 
ADR to prescribed 
treatment  
Susceptible 
patient (falls) 
9 
 
38.   M 2015-0192 Advisory Council on 
Misuse of Drugs 
Acetylfentanyl Opioids He was known to abuse drugs 
and drugs paraphernalia was 
found in the room with him. 
This drug is being marketed 
legally and is available over the 
internet. 
Drug regulation 
inadequate [or 
failure to enforce] 
39.  86 F 2015-0161 Minister of Health for 
Wales 
 
Chief Executive, 
Cwm Taf University 
Health Board 
Warfarin  
Colchicine 
Allopurinol 
Anticoagulants Started on colchicine and 
allopurinol; insufficient 
monitoring; cerebral infarction 
and haemorrhage 
 
 
 
Interaction → ADR 
Monitoring failure 
40.  70 M 2016-0115 Chief Executive, 
Medway NHS 
Foundation Trust 
Teicoplanin Antibiotics Failure to obtain history of 
MRSA. 
Error in recording MRSA status 
Prophylaxis omitted in patient 
with MRSA  
Omission of 
necessary 
treatment 
41.   M 2016-0131 Chief Executive 
North East London 
Foundation Trust 
 
Chief Officer, 
Redbridge CCG 
Citalopram, 
tramadol, 
mirtazapine 
Opioid 
Psychiatric 
Despite history of overdoses, his 
access to medicines was not 
limited. Overdose by ingesting 
excessive amounts of medicines 
Excessive supply 
42.  84 M 2015-0317 National Patient 
Safety Agency  
 
Chief Fire Officer 
Staffordshire 
 
Cetraben 
emollient cream 
 Burned to death ADR to prescribed 
medicines  
Susceptible 
patient (smoker) 
10 
 
Chief Fire Officers 
Association 
43.  ‘elderly’  
F 
2016-0047 Chief Executive, 
West Wales General 
Hospital Glangwili 
Carmarthen 
Low molecular 
weight heparin 
(Tinzaparin) 
Anticoagulants Breakdown of a left gluteal 
haematoma caused by 
tinzaparin therapy. 
Failure of monitoring creatinine 
or effect 
Monitoring failure 
Failure to adjust 
dose 
44.   F 2015-0254 Chief Executive, 
East Kent Hospital 
 
Anticoagulant 
therapy 
Anticoagulants Multiple rib fractures. INR 6. 
Haemothorax. Death 
ADR to prescribed 
medicines 
45.   M 2016-0163 Director of 
Commissioning, 
NHS England, 
Central Midlands 
 
President Chief Fire 
Officers 
 
Chief Executive 
Reckitt Benckiser.  
E45 emollient 
cream 
 Burned to death ADR to prescribed 
medicines 
Susceptible 
patient (smoker) 
 
46.  50 F 2015-0392 New Court Surgery Citalopram Psychiatric Depressed. Hanged. Citalopram 
for 5½ years without review 
Monitoring failure 
47.  66 F 2015-0195 Omitted Antibiotics Antibiotics Necrotizing fasciitis post op; 
inadequate antibiotic therapy 
Omission of 
necessary 
treatment 
48.  83 F 2015-0221 Betsi Cadwaladr 
University Health 
Board 
Risperidone Psychiatric Failure to review medication; 
falls’ fracture femur. Death 
Failure to review 
medication 
ADR to prescribed 
medicines 
49.  58 M 2016-0228 Chief Executive, 
Stockport NHS Trust 
Enoxaparin Anticoagulants Deep vein thrombosis after 
fracture tibia and fibula. 
Inappropriate dose 
for patient 
11 
 
Weighed 99.8 kg. Given dose of 
40 mg. 
Accurate weight is essential 
50.  :50 F 2016-0111 Chesterfield Royal 
Hospital 
Potassium 
chloride 
 Prolonged QT interval, 
ventricular tachycardia, 
hypokalaemia 2.4 mmol/L, 
alcoholic liver disease 
Monitoring failure 
Failure to follow 
protocol 
Omission of 
necessary 
treatment 
51.  1 day  
M 
2015-0377 Medical Director, 
Whittington Hospital 
Oxytocin   Meconium stained liquor. Delay 
in starting Syntocinon® infusion, 
which should have been started 
4½ hours before. Baby died. 
Delayed treatment 
Poor training 
52.   F 2015-0414 University Hospital 
Birmingham 
 
Birmingham 
Women’s NHS 
Foundation Trust 
Low molecular 
weight heparin 
(Enoxaparin) 
Anticoagulants Mechanical mitral valve; advised 
to avoid pregnancy; problem 
with valve; thrombosis of 
prosthetic valve; failure of 
hospital clinicians to prescribe 
adequate doses of enoxaparin 
contributed to the fatal 
thrombosis 
Omission of 
necessary 
treatment 
 
53.  20 M 2015-0191 
J 
Home secretary MDMA Drug of Abuse MDMA – Drug of Abuse only 
(both brothers) obtained via 
Dark Web 
Drug regulation 
inadequate 
 19 M 2015-0191 
T 
Home secretary MDMA Drug of Abuse MDMA – Drug of Abuse only 
(both brothers) obtained via 
Dark Web 
Drug regulation 
inadequate 
54.  25 F 2015-0217 Department of 
Health 
eCigarette fluid Drug of Abuse Ingestion of one bottle → 
multiple organ dysfunction → 
death 
Drug regulation 
inadequate 
12 
 
55.   M 2015-0282 Chief Executive 
University Hospital 
of Wales  
 
Consultant 
Geriatrician 
Morphine Opioids Failure to inform GP of 
inadvertent overdose; 
inadequate systems to inform 
GP 
Poor 
communication 
Poor systems 
(failure to warn of 
potential ADR) 
 
56.  63 F 2016-0174 North Middx Hospital Clozapine Psychiatric ADR → myocarditis  
[Monitoring failure when 
admitted]  
Recommendation not related to 
ADR, but ADR → death 
ADR to prescribed 
medicines 
57.  83 F 2016-0062 Chief Executive 
Officer, East 
Lancashire 
Healthcare  
Low molecular 
weight heparin  
Anticoagulants Fracture of left leg and ankle. ℞ 
LMWH stopped at discharge. 
Deep venous thrombosis, 
pulmonary embolus, death 
 
Omission of 
necessary 
treatment 
 
58.  18 M 2016-0254 Cambridge and 
Peterborough NHS 
Foundation Trust 
 
A GP Practice 
 
CCG  
 
NHS England 
  Antidepressant Psychiatric Seen by a nurse, who 
recommended an 
antidepressant 
GP prescribed anti-depressant 
without seeing patient 
Walked in front of a train 
Failure to warn of 
ADRs 
Failure to take 
history or see 
patient 
Poor 
communication 
59.  78 M 2015-0247 Chief Executive, 
Royal Devon & 
Exeter 
Flucloxacillin Antibiotics Developed cholestatic jaundice 
with flucloxacillin. Discharged 
without notifying GP of this. GP 
Practice nurse prescribed 
flucloxacillin again, provoking a 
fatal reaction 
Poor 
communication 
Failure to warn of 
ADRs 
13 
 
60.  80 F 2016-0156 Manager, Acorn 
Lodge Care Home 
Oxygen  It had been reported that the 
patient had been lying supine on 
the bed saturating at 84% and 
struggling to breath. The oxygen 
could not be heard to be running 
and it was noted that only 1 litre 
was running when this should 
have been a15 litre flow with the 
mask applied. 
Omission of 
necessary 
treatment 
Poor training 
61.  85 M 2016-0171 Chief Executive, 
South Manchester 
University Hospital 
Trust 
Antibiotics Antibiotics Discharged from hospital without 
antibiotics or a discharge letter 
Omission of 
necessary 
treatment 
Poor 
communication 
62.   M 2015-0237 Chief Constable of 
Surrey 
Cocaine 
Amphetamine 
Butylone 
Drug of Abuse Arrested. Taken in a police van. 
Died. Incomplete information 
provided to arresting officers. 
Especially that he had 
previously swallowed class A 
drugs. Drug-related death. 
Poor 
communication 
Failure of training 
63.  36 M 2015-0231 Director of 
Pharmacovigilance, 
MHRA 
Cocaine 
Citalopram 
Psychiatric 
Drug of Abuse 
Blood contained cocaine, 
citalopram, methadone, heroin 
Subarachnoid haemorrhage 
after cocaine while taking 
citalopram 
The drugs led to death 
Interaction  
64.   M 2016-0295 Advisory Council on 
Misuse of Drugs 
Pentobarbital  Self-administered; kept in the 
veterinary practice where 
deceased worked; it is abused. 
Drug regulation 
inadequate 
14 
 
It is only a Schedule 3 drug, not 
Schedule 2. 
65.  48 M 2016-0010 Minister for Policing, 
Fire, and Criminal 
Justice  
 
DVLA Medical 
Branch Chief 
Medical Advisor 
Alcohol 
Synthetic 
cannabinoid 
Drug of Abuse Hanging in prison. Had taken 
legal highs (5F AKB-48, 5F PB-
22)  
Drug regulation 
inadequate 
66.  93 F 2015-0310 Minister of Health 
Wales  
 
Chief Executive 
NHS Wales 
Levothyroxine  Failure to record regular 
medication on admission; 
absence of medicines 
reconciliation policy; thyroxine 
omitted for five weeks 
Omission of 
necessary 
treatment 
Poor systems 
(No medicines 
reconciliation) 
67.  34 M 2016-0224 Governor, HMP 
Rochester 
Anabolic steroid  Drug of Abuse Anabolic-steroid induced 
cardiomyopathy; ventricular 
tachycardia, probable pulmonary 
embolism. Death in prison. 
 
Delayed treatment 
Failure to follow 
protocol 
Inadequate 
training 
68.  1 day  
M 
2015-0177 Department of 
Health; Royal 
College of Obstetrics  
 
NICE 
 
 Royal College of 
Paediatrics 
Antibiotics 
 
Antibiotics Group B streptococcus in 
previous pregnancy; no 
prophylactic antibiotics. Baby 
died from Group B strep 
Omission of 
necessary 
treatment 
 
69.  34 M 2015-0444 Worcestershire 
Health and Care 
Propranolol 
Citalopram 
Psychiatric Asthma; had previously had 
propranolol. This was contra-
Contra-indicated 
15 
 
Olanzapine 
Amitriptyline 
 
indicated, but not noted to be 
contra-indicated in the medical 
records. While attempts had 
been made to stop it, it had 
been reintroduced 
Monitoring failure 
(ECG)  
70.  74 M 2015-0400 Chief Executive, 
Cardiff and Vale 
University Health 
Board 
Noradrenaline  Intensive care after major 
bladder surgery, noradrenaline 
line inadvertently disconnected. 
Failure to label IV lines. No 
protocol for this. 
Omission of 
necessary 
treatment 
Poor systems 
(Lines not 
labelled) 
71.  74 F 2016-0014 Churchgate Surgery; 
Macmillan Cancer 
Care; Takeda 
Fentanyl patch Opioids Took a hot bath while wearing a 
fentanyl patch; died. Death was 
caused by fentanyl toxicity. 
Patient 
Leaflet warns on page 8 of 
‘prolonged hot bath,’ but these 
terms are not defined 
Failure to warn of 
ADRs 
72.  64 M 2016-0246 Doncaster Royal 
Infirmary 
Fluticasone (in 
Seretide®) 
 Pneumonia in a man with lung 
cancer. Inhaled fluticasone 
lowered his immunity. Coroner 
determined that fluticasone is 
not useful if the eosinophil count 
is not raised 
ADR to prescribed 
medicines 
73.  56 F 2015-0295 Director of 
Pharmacovigilance, 
MHRA 
 
Director CCP, NICE  
 
Lisinopril 
Spironolactone 
 Chronic kidney disease, Type 2 
DM, fibromyalgia, heart failure. 
Twenty-two different medicines. 
Non-prescribing nurse printed a 
prescription, then GP signed 
Hyperkalaemia 9.7 mmol/L → 
death 
Interaction 
Poor systems 
(non-prescriber 
decided 
prescription) 
16 
 
Medical Director, 
Lincolnshire 
Community Health 
Service 
74.  54 M 2015-0210 Secretary of State 
for Health 
 
Chief Executive 
Officer, University 
Hospital South 
Manchester 
Warfarin Anticoagulants Failed to attend anticoagulant 
clinic on three occasions; lack of 
a system for repeat prescribing.  
Poor systems 
(for repeat 
prescribing) 
75.  77 F 2015-0423 Chief Executive, HC-
One [Care Homes] 
Low molecular 
weight heparin 
(dalteparin) 
Anticoagulants Fractured neck of femur. Policy 
is to give prophylactic low 
molecular weight heparin for 4 
weeks; documents on discharge 
said 3 weeks; ‘notes inaccurate.’ 
 
Poor 
communication 
(wrong 
information) 
76.  60 F 2016-0197 Chief Executive, 
East Lancashire 
Healthcare NHS 
Trust 
Pharmacological 
thrombo-
prophylaxis  
Anticoagulants Fracture left arm and leg; not 
given appropriate prophylaxis; 
deep; vein thrombosis, death. 
Failure to follow Trust protocol 
Omission of 
necessary 
treatment 
Poor systems 
(Failure to follow 
protocol; e-
prescribing did not 
extent to the 
emergency 
department) 
77.  95 F 2015-0241 Chief Executive, 
Heart of England 
NHS Foundation 
Trust 
Low molecular 
weight heparin 
(enoxaparin) 
and aspirin 
Anticoagulants  Atrial fibrillation, congestive 
heart failure, chronic kidney 
disease. Bled from duodenal 
ulcers. Cirrhosis. 
ADR to prescribed 
medicines  
Interaction 
17 
 
Electronic discharge letter and 
written prescription differed 
78.  23 M 2015-0474 Medical Director, 
Greater Manchester 
NHS Area Team 
 
Chief Executive, 
Greater Manchester 
West Mental Health 
NHS Foundation 
Trust 
 
Bodmin Road Health 
Centre 
Benzodiazepine 
(diazepam) 
Hypnotics and 
sedatives 
Hanging; illicit drugs (benzos) 
and legal highs found. 
Confusion over benzodiazepine 
dose reduction.  
Phoenix Futures (addiction 
support service) cannot 
prescribe 
Poor 
communication 
79.   M 2016-0017 Chief Executive, 
Stockport NHS 
Foundation Trust 
Insulin levemir  Accidentally omitted 
Died of diabetic keto-acidosis 
Omission of 
necessary 
treatment 
 
80.   2016-0242 Chief Executive. 
Central Manchester 
University Hosp 
NHS Foundation 
Trust 
Co-amoxiclav Antibiotics Given prophylactically 
Known to have penicillin allergy 
by GP letter; co-amoxiclav 
contains a penicillin. Patient 
given co-amoxiclav, developed 
toxic epidermal necrolysis, and 
died. 
Contra-indication 
ADR to prescribed 
medicines 
81.  94 M 2016-0075 Chief Executive, 
Barts Health 
Opiates 
(morphine 
sulfate, 
codeine, 
fentanyl via 
epidural) 
Opioids Fall at home. Dynamic hip 
screw; pain managed with 
opiates; gradually increasing 
opiate toxicity led to aspiration 
pneumonia and death 
 
ADR to prescribed 
medicines 
Failure to adjust 
dose 
Susceptible 
patient 
18 
 
82.  35 M 2015-0298 Dorset Healthcare 
University NHS 
Foundation Trust 
HMP Exeter 
Methadone Opioids Known abuser of heroin, 
amphetamine, diazepam, 
cannabis. No drugs for weeks 
before admission.  Risk of self-
harm. Under 30–60 minute 
observation. Given medication 
for ‘seizures and detoxification; 
dead in the morning 
ADR to prescribed 
medicines 
Monitoring failure 
Poor systems 
Poor 
Communication 
83.  32 M 2015-0382 Governor, HMP 
Hewell 
Worcestershire 
Health & Care Trust 
Methadone 
Mirtazapine 
Olanzapine 
Zopiclone 
Opioids 
Psychiatric 
Hypnotics and 
sedatives 
Known high risk drug taker who 
took prescribed and other 
medicines in his cell. Death in 
prison 
Failure to 
appreciate risk (of 
illicit drug-taking) 
Poor 
communication 
Monitoring failure 
84.  29 M 2016-0042 Secretary of State 
for Health 
Acetylfentanyl Opioids ‘Legal high’ Drug regulation 
inadequate 
85.   F 2015-0199 Chief Executive, 
Surrey & Sussex 
Healthcare 
 
Chief Executive, 
Surrey & Borders 
Partnership 
30 sleeping 
tablets 
 
 Overdose. But Coroner’s 
concern was the 
misunderstandings arising from 
untrained staff as interpreters; 
and poor assessment 
Poor 
communication 
(unqualified 
interpreter) 
Inadequate 
training 
Failure to 
appreciate risk 
86.  45 F 2016-0123 Chief Executive, 
MHRA 
Opiates 
Morphine 
Tramadol 
Opioids 
Psychiatric 
Escalating dose of oral 
morphine: 100 → 280 → 500 ml 
ADR to prescribed 
medicines 
19 
 
Pregabalin 
Mirtazapine 
Morphine 10 mg/5 ml is not 
subject to constraints (Schedule 
5 of the Misuse of Drugs Act.) 
Then died. 500 ml could be 
issued without control 
Failure to adjust 
dose 
Drug regulation 
inadequate 
 
87.  36 M 2016-0081 A GP Practice Mirtazapine 
Pregabalin 
Psychiatric Hanged; treatment was stopped 
by doctors at acute hospital 
pending review; not reviewed 
before his suicide. 
Concern: the effectiveness of 
existing office systems and 
procedures in relation to the 
receipt of discharge summaries 
from hospitals which advise on 
the review of patient’s 
medication. 
Poor systems 
(advice on review 
of medication) 
88.  17 M 2016-0176 Medical Director, 
East London NHS 
Foundation Trust 
Cannabis 
MDMA 
Drug of Abuse Taken to hospital with 
a drug related 
psychotic episode after 
having taken cannabis 
and ecstasy at a music 
festival. Assessed. 
Discharged with no 
plan. Deteriorated. 
Police officers saw him 
running towards a river. 
One gave chase. Jack 
jumped in the river and 
drowned. 
 
Poor 
communication 
Failure to 
appreciate risk (of 
recurrent or 
continued 
symptoms) 
Poor systems 
20 
 
89.  79 F 2016-0096 General Dental 
Council  
 
British Medical 
Association  
 
Royal 
Pharmaceutical 
Society 
 
Royal College of 
GPs 
  
NHS England, 
Wales, Scotland 
Warfarin 
Miconazole gel 
Anticoagulants 
Antibiotics 
Atrial fibrillation on warfarin 
Two weeks before admission: 
miconazole gel for oral thrush 
Intracerebral haemorrhage 
INR (clotting test) > 10 
[Therapeutic 2.5]. 
Died 
 
Interaction: ADR 
to prescribed 
medicines 
90.  36 M T2015-0309 Chief Executive, 
Norfolk & Suffolk 
NHS Foundation 
Trust 
Medication for 
psychiatric 
disease 
Psychiatric Medication changed. 
Psychiatrist warned of the need 
to monitor. Care coordinator did 
not know what to look for.  
Monitoring failure  
Poor 
communication 
Failure of training 
91.  86 M 2016-0079 Chief Executive, 
Royal 
Pharmaceutical 
Society 
Chief Executive, 
Dispensing Doctors’ 
Association 
Finasteride  Finasteride comes in a blister 
pack. Snipped and placed in 
MCCA. Deceased swallowed a 
tablet still in its blister pack. It 
perforated the gut and he died.  
Professional bodies advise 
against this. 
Failure to follow 
recommended 
practice 
92.   M 2015-0262 Minister for Health, 
Wales 
 
Warfarin Anticoagulants Warfarin for metallic heart valve 
Missed an INR check; continued 
prescribing without any check; 
then warfarin prescription was 
discontinued. Pharmacist 
Monitoring failure 
21 
 
Chief Executive 
Cwm Taf University 
Health Board  
 
A GP Practice 
 
Primary Clinical 
Director, Aneurin 
Bevan University 
Health Board 
 
Consultant 
Psychiatrist, North 
Community Mental 
Health Team 
nonetheless supplied it; the 
patient died from gut 
haemorrhage 
93.  96 F 2016-0080 Chief Executive 
Officer, Stockport 
NHS Foundation 
Trust 
Co-trimoxazole 
Teicoplanin 
Antibiotics Knee replacement about 2000. 
The knee became septic. No 
antibiotics were given for 48h. 
Then he was treated with co-
trimoxazole. He was also 
prescribed teicoplanin (but this 
was omitted for 24h). He 
developed disseminated 
intravascular coagulation and 
died 
Omission of 
necessary 
treatment 
(teicoplanin) 
ADR to prescribed 
medicines (co-
timoxazole) 
94.   M 2015-0437 Medical Director, 
Barts Health 
Heparin Anticoagulants Unwitnessed fall; fractured hip 
and shoulder, confused with 
heparin. 
ADR to prescribed 
medicines 
95.  37 M 2016-0249 Practice Manager, 
GP Medical Centre;  
 
Opioids 
Codeine 
Methadone 
Opioids 
Hypnotics and 
sedatives 
Drank alcohol and developed 
bronchopneumonia. In hospital, 
Interaction—ADR 
to prescribed 
medicines 
22 
 
Medical Director 
NHS England  
 
Medical Director,   
Greater Manchester 
Clonazepam and given naloxone. Self-
discharged 
Given daily meds 
‘Although the prescription was 
stopped, it was started again in 
error’ (clonazepam).’ Found 
dead in bed 
Poor systems 
(erroneous 
reinstatement of 
prescription) 
96.   M 2016-0245 Governor, Leicester 
Prison 
Cannabinoid Drug of Abuse Hanging in prison cell – ‘low 
traces of Mamba’ — unclear of 
relevance of Mamba. 
Inadequate observation. 
Inappropriate delay in help. 
Monitoring failure 
Delayed treatment 
(of hanging) 
97.   F 2016-0049 Chief Executive, 
Sainsbury’s 
 
Chief Executive 
Oadby & Wigston 
Borough Council 
 
Chief Executive, 
HSE 
Warfarin Anticoagulants On warfarin; fell when lift doors 
opened without warning; hit 
head. Suffered a large subdural 
bleed and died 
ADR to prescribed 
medicines (action 
relates to door 
opening) 
98.  87 F 2015-0169 Newgate Medical 
Group 
Warfarin Anticoagulants Atrial fibrillation. INR 8.0, Fall 
while the INR was high, in spite 
of vitamin K, developed 
intracerebral haemorrhage, and 
died. 
Monitoring failure: 
poor systems 
(prescribing and 
monitoring 
warfarin treatment) 
99.   M 2016-0308 MHRA Hyoscine 
butylbromide  
 Given hyoscine butylbromide 
during routine colonoscopy. 
Sudden deterioration. Cardiac 
arrest. Died 
ADR to prescribed 
medicines 
Poor awareness of 
rare ADRs 
23 
 
Risk of ADR not widely known. 
Summary of Product 
Characteristics is unsatisfactory. 
Requires amendment. 
Susceptible 
patient (ischaemic 
heart disease – 
undiagnosed) 
 
Abbreviations: A&E – Accident and Emergency Department; ADR – adverse drug reaction; DVLA – Driver and Vehicle Licensing Authority; GP 
– General Practitioner; HMP – Her Majesty’s Prison; HSE – Health & Safety Executive; INR – international normalized ratio; LMWH – low 
molecular weight heparin; MCCA – multi-compartment compliance aid; MDMA = 3,4-methylenedioxymethamphetamine; MHRA – Medicines 
and Healthcare products Regulatory Agency; MRSA – methicillin-resistant Staphylococcus aureus; NHS 111 – National Health Service 
telephone urgent and emergency care service; NICE – National Institute for Health and Care Excellence.  
